3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
18
Lymphoma, B-Cell, Marginal Zone
6
Stomach Neoplasms
4
Neoplasms, Plasma Cell
4
Lymphoma
4
Dyspepsia
3
Recurrence
2
Peptic Ulcer
2
Gastritis
2
Skin Neoplasms
1
Pseudomyxoma Peritonei
1
Prostatic Neoplasms
1
Persistence of Infection With Helicobacter Pylori
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leukemia, B-Cell
1
Infections
1
Helicobacter Infections
1
Familial primary gastric lymphoma
1
Chemotherapy Effect
1
Carcinoma, Non-Small-Cell Lung
1
Cachexia
1
Appendiceal Neoplasms
1
Interventions
Cyclophosphamide
10
fludarabine
7
Rituximab
6
Bendamustine Hydrochloride
5
venetoclax
4
obinutuzumab
4
Lenalidomide
4
ofatumumab
3
ibrutinib
3
fludarabine phosphate
3
acalabrutinib
3
Vincristine
3
Immunotherapy, Adoptive
3
pirtobrutinib
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
ricolinostat
1
pembrolizumab
1
pegaspargase
1
nelarabine
1
idelalisib
1
blinatumomab
1
Whole-Body Irradiation
1
Prednisolone
1
Pentostatin
1
Panobinostat
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, B-Cell
×
Clarithromycin
×
Clear all
NCT01279252
2019-01-25
CLEAR
King's College Hospital NHS Trust
Phase 2
Completed
71 enrolled